DPP4 and plasma cell myeloma: In the current study, we elucidated for the first time the potential impacts and mechanisms of HDACi by isoform-selective as well as broad inhibitors on the regulation of CD26 expression in myeloma cells, thereby eliciting superior anti-myeloma efficacy by CD26mAb.